PL1737962T3 - Uniwersalny lider GAS1 - Google Patents

Uniwersalny lider GAS1

Info

Publication number
PL1737962T3
PL1737962T3 PL05729650T PL05729650T PL1737962T3 PL 1737962 T3 PL1737962 T3 PL 1737962T3 PL 05729650 T PL05729650 T PL 05729650T PL 05729650 T PL05729650 T PL 05729650T PL 1737962 T3 PL1737962 T3 PL 1737962T3
Authority
PL
Poland
Prior art keywords
heavy chain
chain variable
variable domain
immunoglobulin heavy
domain polypeptide
Prior art date
Application number
PL05729650T
Other languages
English (en)
Inventor
Wildt Rudolph M T De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of PL1737962T3 publication Critical patent/PL1737962T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gas Separation By Absorption (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05729650T 2004-03-24 2005-03-24 Uniwersalny lider GAS1 PL1737962T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55576404P 2004-03-24 2004-03-24
EP05729650A EP1737962B1 (en) 2004-03-24 2005-03-24 Gas1 universal leader
PCT/GB2005/001180 WO2005093074A1 (en) 2004-03-24 2005-03-24 Gas1 universal leader

Publications (1)

Publication Number Publication Date
PL1737962T3 true PL1737962T3 (pl) 2011-02-28

Family

ID=34963448

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05729650T PL1737962T3 (pl) 2004-03-24 2005-03-24 Uniwersalny lider GAS1

Country Status (11)

Country Link
US (1) US7846721B2 (pl)
EP (2) EP2172553A1 (pl)
AT (1) ATE479760T1 (pl)
CY (1) CY1111063T1 (pl)
DE (1) DE602005023291D1 (pl)
DK (1) DK1737962T3 (pl)
ES (1) ES2351509T3 (pl)
PL (1) PL1737962T3 (pl)
PT (1) PT1737962E (pl)
SI (1) SI1737962T1 (pl)
WO (1) WO2005093074A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
KR101740066B1 (ko) 2008-12-05 2017-05-25 글락소 그룹 리미티드 프로테아제 저항성 폴리펩티드를 선택하는 방법
SG173488A1 (en) 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
CA2767752C (en) 2009-02-19 2020-07-07 Glaxo Group Limited Improved anti-serum albumin binding variants
CN102405236A (zh) 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
EP2453920A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
JP2012532620A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
BR112012001977A2 (pt) 2009-07-29 2017-01-31 Glaxo Group Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar.
EP2523686A2 (en) 2010-01-14 2012-11-21 Glaxo Group Limited Liver targeting domain antibodies
EP2560992A2 (en) 2010-04-21 2013-02-27 Glaxo Group Limited Binding domains
AU2011254559B2 (en) 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
WO2012021749A1 (en) * 2010-08-11 2012-02-16 Celula, Inc. Genotyping dna
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
JP2013537421A (ja) 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
JP6062375B2 (ja) 2011-01-06 2017-01-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド
US20130310281A1 (en) 2011-02-02 2013-11-21 Glaxo Group Limited Novel antigen binding proteins
BR112013026828A2 (pt) 2011-04-21 2016-11-29 Bristol Myers Squibb Co polipeptídeos de anticorpo que antagonizam cd40
EP3578660A1 (en) * 2012-07-05 2019-12-11 F. Hoffmann-La Roche AG Expression and secretion system
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression

Also Published As

Publication number Publication date
EP2172553A1 (en) 2010-04-07
EP1737962B1 (en) 2010-09-01
ATE479760T1 (de) 2010-09-15
US7846721B2 (en) 2010-12-07
EP1737962A1 (en) 2007-01-03
WO2005093074A1 (en) 2005-10-06
DK1737962T3 (da) 2010-12-13
DE602005023291D1 (de) 2010-10-14
CY1111063T1 (el) 2015-06-11
PT1737962E (pt) 2010-12-03
US20070026462A1 (en) 2007-02-01
ES2351509T3 (es) 2011-02-07
SI1737962T1 (sl) 2011-01-31

Similar Documents

Publication Publication Date Title
CY1111063T1 (el) Καθολικος οδηγος gas1
NZ734307A (en) Antibodies specific for claudin 6 (cldn6)
PT1523496E (pt) Produção de misturas de anticorpos de forma recombinante
DK1831362T3 (da) Syreaktive svampeproteaser
NZ603037A (en) Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
EP2395092A3 (en) Plants having enhanced yield-related traits and a method for making the same
EP1625163B8 (en) Method of detecting probnp with a monoclonal antibody binding to the amino acids 38-43
ATE402267T1 (de) Verfahren zur herstellung von monoklonalen antikörpern
WO2006116657A3 (en) Single-chain antibody with cleavable linker
ATE513788T1 (de) Verfahren zur reinigung von lithiumsulfid
ATE454455T1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
ATE424458T1 (de) Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung
WO2003004622A3 (en) Human secreted proteins
WO2004033631A8 (en) Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
DK1609863T3 (da) Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
WO2003000865A3 (en) Human secreted proteins
DE502006009060D1 (de) Verfahren zur fermentativen Herstellung von Antikörpern
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
ATE320484T1 (de) Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
WO2009028531A1 (ja) ドックリンポリペプチドおよびそれを利用した組換え融合タンパク質の精製方法
EP1678308A4 (en) Expression vector for secreting antibody fragment using e. coli signal sequence and method for mass-producing antibody fragment
WO2008008182A3 (en) Method of production of para-hydroxycinnamic acid
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
ATE531799T1 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper